Insmed (NASDAQ:INSM) Price Target Raised to $82.00 at Mizuho

Insmed (NASDAQ:INSMFree Report) had its target price hoisted by Mizuho from $36.00 to $82.00 in a report issued on Friday morning, Benzinga reports. Mizuho currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on INSM. TD Cowen increased their price target on Insmed from $45.00 to $67.00 and gave the company a buy rating in a report on Wednesday, May 29th. The Goldman Sachs Group increased their price target on Insmed from $49.00 to $74.00 and gave the company a buy rating in a report on Wednesday, May 29th. UBS Group increased their price objective on Insmed from $46.00 to $58.00 and gave the stock a buy rating in a research report on Wednesday, May 29th. StockNews.com upgraded Insmed from a sell rating to a hold rating in a research report on Tuesday, May 14th. Finally, Stifel Nicolaus increased their price objective on Insmed from $39.00 to $67.00 and gave the stock a buy rating in a research report on Friday, May 31st. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Insmed presently has an average rating of Moderate Buy and an average target price of $59.25.

Get Our Latest Research Report on INSM

Insmed Stock Down 0.6 %

NASDAQ:INSM opened at $56.85 on Friday. Insmed has a one year low of $18.77 and a one year high of $58.99. The stock has a 50 day moving average price of $31.05 and a 200 day moving average price of $28.99.

Insmed (NASDAQ:INSMGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.16. The company had revenue of $75.50 million during the quarter, compared to analyst estimates of $77.76 million. During the same period in the prior year, the business posted ($1.17) EPS. Insmed’s revenue for the quarter was up 15.8% compared to the same quarter last year. As a group, equities analysts forecast that Insmed will post -4.51 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other news, insider Martina M.D. Flammer sold 21,195 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $55.00, for a total value of $1,165,725.00. Following the sale, the insider now directly owns 106,134 shares in the company, valued at $5,837,370. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider John Drayton Wise sold 5,088 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $25.47, for a total value of $129,591.36. Following the sale, the insider now directly owns 123,259 shares in the company, valued at $3,139,406.73. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Martina M.D. Flammer sold 21,195 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $55.00, for a total value of $1,165,725.00. Following the completion of the sale, the insider now owns 106,134 shares in the company, valued at $5,837,370. The disclosure for this sale can be found here. Insiders sold a total of 295,842 shares of company stock worth $13,762,062 over the last ninety days. Company insiders own 4.60% of the company’s stock.

Institutional Trading of Insmed

Hedge funds have recently modified their holdings of the stock. International Assets Investment Management LLC acquired a new stake in Insmed in the fourth quarter valued at $25,000. EntryPoint Capital LLC acquired a new stake in Insmed in the first quarter valued at $33,000. Fidelis Capital Partners LLC acquired a new stake in Insmed in the first quarter valued at $34,000. Headlands Technologies LLC acquired a new stake in Insmed in the first quarter valued at $59,000. Finally, Quarry LP acquired a new stake in Insmed in the fourth quarter valued at $116,000.

About Insmed

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Further Reading

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.